Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.

Antimicrobial agents and chemotherapy - 1 Jan 2016

Hennig Stefanie, Naiker Suhashni, Reddy Tarylee, Egan Deirdre, Kellerman Tracy, Wiesner Lubbe, Owen Andrew, McIlleron Helen, Pym Alexander

Abstract excerpt

Rifabutin, used to treat HIV-infected tuberculosis, shows highly variable drug exposure, complicating dosing. Effects of SLCO1B1 polymorphisms on rifabutin pharmacokinetics were investigated in 35 African HIV-infected tuberculosis patients after multiple doses. Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Ethambutol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoniazid

Share to Liver-Specific Organic Anion Transporter 1

Share to Monte Carlo Method

Share to Organic Anion Transporters

Share to Pyrazinamide

Share to Rifampin

Source

Open in PubMed Open full text

Identifiers

PMID: 26482301
DOI: 10.1128/AAC.01195-15
PMCID: PMC4704238

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.PMID 26482301Read ↗

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.Semantic proximity Read ↗

Genetic Diversity in Drug Transporters: Impact in African PopulationsSemantic proximity Read ↗

Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Semantic proximity Read ↗

Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.Semantic proximity Read ↗

Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.Semantic proximity Read ↗

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.Semantic proximity Read ↗

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis PatientsSemantic proximity Read ↗

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Semantic proximity Read ↗

In-silico functional prediction of novel tuberculosis pharmacogenetic variants and NAT2 phenotype prediction in African populationsSemantic proximity Read ↗

A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.Semantic proximity Read ↗

SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico.Semantic proximity Read ↗

Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.